Compare BILI & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILI | PTCT |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.0B |
| IPO Year | 2017 | 2006 |
| Metric | BILI | PTCT |
|---|---|---|
| Price | $11.04 | $58.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 30 | 15 |
| Target Price | $24.74 | ★ $100.47 |
| AVG Volume (30 Days) | ★ 3.1M | 934.6K |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 0.34 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $7.74 | N/A |
| Revenue Next Year | $10.45 | $8.29 |
| P/E Ratio | ★ $122.37 | $177.18 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $11.51 | $58.80 |
| 52 Week High | $36.40 | $90.87 |
| Indicator | BILI | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 25.29 | 38.39 |
| Support Level | N/A | N/A |
| Resistance Level | $19.10 | $69.74 |
| Average True Range (ATR) | 0.37 | 2.46 |
| MACD | -0.23 | -0.54 |
| Stochastic Oscillator | 0.00 | 1.34 |
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.